Duloxetine Lilly

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
21-12-2021
Karakteristik produk Karakteristik produk (SPC)
21-12-2021

Bahan aktif:

duloxetine

Tersedia dari:

Eli Lilly Nederland B.V.

Kode ATC:

N06AX21

INN (Nama Internasional):

duloxetine

Kelompok Terapi:

Psychoanaleptics,

Area terapi:

Neuralgia; Diabetic Neuropathies; Depressive Disorder, Major

Indikasi Terapi:

Duloxetine Lilly is indicated in adults for:Treatment of major depressive disorderTreatment of diabetic peripheral neuropathic painTreatment of generalised anxiety disorderDuloxetine Lilly is indicated in adults.

Ringkasan produk:

Revision: 9

Status otorisasi:

Authorised

Tanggal Otorisasi:

2014-12-08

Selebaran informasi

                                34
B. PACKAGE LEAFLET
35
PACKAGE LEAFLET: INFORMATION FOR THE USER
DULOXETINE LILLY
30 MG
HARD GASTRO-RESISTANT CAPSULES
DULOXETINE LILLY 60 MG
HARD GASTRO-RESISTANT CAPSULES
duloxetine (as hydrochloride)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any of the side effects talk to your doctor or pharmacist.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What Duloxetine Lilly is and what it is used for
2.
What you need to know before you take Duloxetine Lilly
3.
How to take Duloxetine Lilly
4.
Possible side effects
5.
How to store Duloxetine Lilly
6.
Contents of the pack and other information
1.
WHAT DULOXETINE LILLY IS AND WHAT IT IS USED FOR
Duloxetine Lilly contains the active substance duloxetine. Duloxetine
Lilly increases the levels of
serotonin and noradrenaline in the nervous system.
Duloxetine Lilly is used in adults to treat:
•
depression
•
generalised anxiety disorder (chronic feeling of anxiety or
nervousness)
•
diabetic neuropathic pain (often described as burning, stabbing,
stinging, shooting or aching or
like an electric shock. There may be loss of feeling in the affected
area, or sensations such as
touch, heat, cold or pressure may cause pain)
Duloxetine Lilly starts to work in most people with depression or
anxiety within two weeks of starting
treatment, but it may take 2-4 weeks before you feel better. Tell your
doctor if you do not start to feel
better after this time. Your doctor may continue to give you
Duloxetine Lilly when you are feeling
better to prevent your depression or anxiety from returning
In people with diabetic neuropathic pain it can take some weeks befor
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
_ _
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Duloxetine Lilly 30 mg hard gastro-resistant capsules
Duloxetine Lilly 60 mg hard gastro-resistant capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Duloxetine Lilly 30
mg
Each capsule contains 30 mg of duloxetine (as hydrochloride).
_Excipient(s) with known effect _
Each capsule may contain up to 56 mg sucrose.
Duloxetine Lilly 60
mg
Each capsule contains 60 mg of duloxetine (as hydrochloride).
_Excipient(s) with known effect _
Each capsule may contain up to 111 mg sucrose.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard gastro-resistant capsule.
Duloxetine Lilly 30
mg
Opaque white body, imprinted with ‘30 mg’ and an opaque blue cap,
imprinted with ‘9543’.
Duloxetine Lilly 60
mg
Opaque green body, imprinted with ‘60 mg’ and an opaque blue cap,
imprinted with ‘9542’.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Treatment of major depressive disorder.
Treatment of diabetic peripheral neuropathic pain.
Treatment of generalised anxiety disorder.
Duloxetine Lilly is indicated in adults.
For further information see section 5.1.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_Major depressive disorder_
The starting and recommended maintenance dose is 60 mg once daily with
or without food. Dosages
above 60 mg once daily, up to a maximum dose of 120 mg per day have
been evaluated from a safety
perspective in clinical trials. However, there is no clinical evidence
suggesting that patients not
responding to the initial recommended dose may benefit from dose
up-titrations.
Therapeutic response is usually seen after 2-4 weeks of treatment.
3
After consolidation of the antidepressive response, it is recommended
to continue treatment for several
months, in order to avoid relapse. In patients responding to
duloxetine, and with a history of repeated
episodes of major depression, further long-term treatment at a dose of
60 to 120 mg/day could be
considered.
_Generalised anxiety disorder_

                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 21-12-2021
Karakteristik produk Karakteristik produk Bulgar 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Bulgar 26-01-2015
Selebaran informasi Selebaran informasi Spanyol 21-12-2021
Karakteristik produk Karakteristik produk Spanyol 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Spanyol 26-01-2015
Selebaran informasi Selebaran informasi Cheska 21-12-2021
Karakteristik produk Karakteristik produk Cheska 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Cheska 26-01-2015
Selebaran informasi Selebaran informasi Dansk 21-12-2021
Karakteristik produk Karakteristik produk Dansk 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Dansk 26-01-2015
Selebaran informasi Selebaran informasi Jerman 21-12-2021
Karakteristik produk Karakteristik produk Jerman 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Jerman 26-01-2015
Selebaran informasi Selebaran informasi Esti 21-12-2021
Karakteristik produk Karakteristik produk Esti 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Esti 26-01-2015
Selebaran informasi Selebaran informasi Yunani 21-12-2021
Karakteristik produk Karakteristik produk Yunani 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Yunani 26-01-2015
Selebaran informasi Selebaran informasi Prancis 21-12-2021
Karakteristik produk Karakteristik produk Prancis 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Prancis 26-01-2015
Selebaran informasi Selebaran informasi Italia 21-12-2021
Karakteristik produk Karakteristik produk Italia 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Italia 26-01-2015
Selebaran informasi Selebaran informasi Latvi 21-12-2021
Karakteristik produk Karakteristik produk Latvi 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Latvi 26-01-2015
Selebaran informasi Selebaran informasi Lituavi 21-12-2021
Karakteristik produk Karakteristik produk Lituavi 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Lituavi 26-01-2015
Selebaran informasi Selebaran informasi Hungaria 21-12-2021
Karakteristik produk Karakteristik produk Hungaria 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Hungaria 26-01-2015
Selebaran informasi Selebaran informasi Malta 21-12-2021
Karakteristik produk Karakteristik produk Malta 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Malta 26-01-2015
Selebaran informasi Selebaran informasi Belanda 21-12-2021
Karakteristik produk Karakteristik produk Belanda 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Belanda 26-01-2015
Selebaran informasi Selebaran informasi Polski 21-12-2021
Karakteristik produk Karakteristik produk Polski 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Polski 26-01-2015
Selebaran informasi Selebaran informasi Portugis 21-12-2021
Karakteristik produk Karakteristik produk Portugis 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Portugis 26-01-2015
Selebaran informasi Selebaran informasi Rumania 21-12-2021
Karakteristik produk Karakteristik produk Rumania 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Rumania 26-01-2015
Selebaran informasi Selebaran informasi Slovak 21-12-2021
Karakteristik produk Karakteristik produk Slovak 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Slovak 26-01-2015
Selebaran informasi Selebaran informasi Sloven 21-12-2021
Karakteristik produk Karakteristik produk Sloven 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Sloven 26-01-2015
Selebaran informasi Selebaran informasi Suomi 21-12-2021
Karakteristik produk Karakteristik produk Suomi 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Suomi 26-01-2015
Selebaran informasi Selebaran informasi Swedia 21-12-2021
Karakteristik produk Karakteristik produk Swedia 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Swedia 26-01-2015
Selebaran informasi Selebaran informasi Norwegia 21-12-2021
Karakteristik produk Karakteristik produk Norwegia 21-12-2021
Selebaran informasi Selebaran informasi Islandia 21-12-2021
Karakteristik produk Karakteristik produk Islandia 21-12-2021
Selebaran informasi Selebaran informasi Kroasia 21-12-2021
Karakteristik produk Karakteristik produk Kroasia 21-12-2021
Laporan Penilaian publik Laporan Penilaian publik Kroasia 26-01-2015

Peringatan pencarian terkait dengan produk ini